IP Library Granted Patent US 8,383,801
Granted Patent B2
US 8,383,801 · App. 12/950,094 · Granted Feb 26, 2013

Polynucleotide encoding a sclerostin-binding antibody

Inventor: Christopher J. Paszty (Ventura, CA)
Assignee: Amgen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,801
App. No.
12/950,094
Granted
Feb 26, 2013
Kind
B2
Abstract

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Claims (26)

1. An isolated polynucleotide comprising a nucleotide sequence encoding a variable region of an antibody or fragment thereof that binds sclerostin of SEQ ID NO: 1, said variable region comprising (a) complementarity determining region (CDR)-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, and CDR-H3 of SEQ ID NO:247 or (b) CDR-L1 of SEQ ID NO:78, CDR-L2 of SEQ ID NO:79 and CDR-L3 of SEQ ID NO:80, or both.

2. The polynucleotide of claim 1 comprising a nucleotide sequence encoding a light chain variable region comprising CDR-L1 of SEQ ID NO:78, CDR-L2 of SEQ ID NO:79, and CDR-L3 of SEQ ID NO:80.

3. The polynucleotide of claim 2 , further comprising a nucleotide sequence encoding a light chain constant region.

4. The polynucleotide of claim 1 comprising a nucleotide sequence encoding a heavy chain variable region comprising CDR-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, and CDR-H3 of SEQ ID NO:247.

5. The polynucleotide of claim 4 , further comprising a nucleotide sequence encoding an IgG4 or an IgG2 constant region.

6. The polynucleotide of claim 1 , further comprising a nucleotide sequence encoding a light chain and/or heavy chain constant region.

7. The polynucleotide of claim 1 , wherein the antibody or fragment demonstrates a binding affinity (Kd) for sclerostin of SEQ ID NO: 1 of less than or equal to about 10 −7 M.

8. The polynucleotide of claim 1 , wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

9. The polynucleotide of claim 1 , wherein the antibody is a monoclonal antibody.

10. The polynucleotide of claim 1 , wherein the antibody comprises an F(ab′)2, Fab, Fab′, Fv, Fc, or Fd fragment.

11. A cloning or expression vector comprising one or more polynucleotide sequences according to claim 1 .

12. The vector of claim 11 , wherein the vector comprises at least one polynucleotide sequence set forth in SEQ ID NO:134, 136, 138, 140, 142, 144, 146, 148, 377, and 379.

13. A host cell comprising one or more cloning or expression vectors according to claim 11 .

14. A host cell comprising one or more cloning or expression vectors according to claim 12 .

15. A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 378.

16. The polynucleotide of claim 15 , wherein the nucleotide sequence encodes a heavy chain of SEQ ID NO:145 or 392.

17. A cloning or expression vector comprising the polynucleotide of claim 15 .

18. A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 376.

19. The polynucleotide of claim 18 , wherein the nucleotide sequence encodes a light chain of SEQ ID NO: 141.

20. A cloning or expression vector comprising the polynucleotide of claim 18 .

21. A host cell comprising the polynucleotide of claim 15 and the polynucleotide of claim 18 .

22. A host cell comprising the polynucleotide of claim 16 and the polynucleotide of claim 19 .

23. A process for producing an antibody or fragment thereof, comprising culturing the host cell of claim 13 and isolating the antibody or fragment.

24. A process for producing an antibody or fragment thereof, comprising culturing the host cell of claim 14 and isolating the antibody or fragment.

25. A process for producing of an antibody or fragment thereof, comprising culturing the host cell of claim 21 and isolating the antibody or fragment.

26. A process for producing of an antibody or fragment thereof, comprising culturing the host cell of claim 22 and isolating the antibody or fragment.

Continuity (7)
Division 12276889 · Nov 24, 2008
Division 11411003 · Apr 25, 2006
Provisional Application 60677583 · May 3, 2005
Provisional Application 60776847 · Feb 24, 2006
Provisional Application 60782244 · Mar 13, 2006
Provisional Application 60792645 · Apr 17, 2006
Related Publication 20110097342A1 · Apr 28, 2011